PAR 5.77% 24.5¢ paradigm biopharmaceuticals limited..

Competition???

  1. 211 Posts.
    lightbulb Created with Sketch. 37
    SCN9A under Phase 2 in Australia, the Company is Olipass, does anyone reckon this could be competition?
    OliPass Peptide Nucleic Acid (OliPass PNA) was derived from PNA by rationally introducing cationic lipid moiety onto nucleobase. By covalently attaching such cationic lipid groups onto PNA, the cell permeability markedly improved. In addition, the affinity for RNA increased by at least a million times.
    SCN9A non-opioid painkiller
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
(20min delay)
Last
24.5¢
Change
-0.015(5.77%)
Mkt cap ! $85.70M
Open High Low Value Volume
26.0¢ 26.0¢ 24.5¢ $265.4K 1.050M

Buyers (Bids)

No. Vol. Price($)
8 130186 24.5¢
 

Sellers (Offers)

Price($) Vol. No.
25.0¢ 11571 1
View Market Depth
Last trade - 16.10pm 31/07/2024 (20 minute delay) ?
PAR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.